Tony Pawson (1952–2013)  by Schlessinger, Joseph
Leading Edge
ObituaryTony Pawson
(1952–2013)Tony PawsonTony Pawson, a world-renowned scien-
tist and a pioneer who made ground-
breaking contributions that shaped our
current understanding of how cellular
signal transduction pathways are regu-
lated in normal tissues and in cancer cells,
sadly passed away on August 7, 2013 at
the age of 60.
Anthony James Pawson was born on
October 18, 1952 in Maidstone in the
County of Kent in England. His mother
was a high school biology teacher with a
special interest in botany. His father was
a well-known soccer player who played
for the Oxford University team and for the
English soccer team at the 1952Olympiad
in Helsinki. His father was also a success-
ful cricket player, a member of the English
fly-fishing team for the 1989 world cham-
pionship, and, later in life, an author and
correspondent for the Observer. Tony
mentioned that he obtained his interest in
science and the natural world from his
mother, but his passion for writing, his
competitiveness, his determination, and
his own love of fly fishing from his father.
After spending his school years at
Winchester College, Tony received his
undergraduate education as a member
of Clare College at Cambridge University.
In Cambridge, he became interested in
biochemistry and had the opportunity to
spend time in the laboratory performing
experiments in the field of protein synthe-
sis. In 1973, Tonymoved to London for his
Ph.D. degree at ICRF (Imperial Cancer
Research Fund, which is now called
Cancer Research UK) with Alan Smith.
During Tony’s Ph.D. studies, the focus of
his research was the mode of action and
mechanism of oncogenesis mediated by
retroviruses and how retroviruses propa-
gate themselves. After obtaining his Ph.D.
in 1976, Tony crossed the Atlantic and
worked at the laboratory of Steven Martin
at the University of California, Berkeley.
Martin focused on investigating themech-
anism of action of Rous Sarcoma virus, a
retrovirus that causes tumors in chickens
and transforms cultured cells by express-
ing its oncogenic protein, v-Src. During
his postdoctoral training, Tony started to1180 Cell 154, September 12, 2013 ª2013 Elexplore the structure and mechanism of
action of the Fujinami avian sarcoma
virus and the role played by its oncogenic
protein, v-Fps, in cell transformation.
In 1981, Tony took an independent
faculty position at the University of
British Columbia in Vancouver, where he
continued to investigate the oncogenic
v-Fps protein, increasingly focused on
the role of its tyrosine kinase activity in
cell transformation. A few years later,
in 1985, Tony moved to the Samuel
Lunenfeld Research Institute at Toronto’s
Mount Sinai Hospital, where he became
Distinguished Investigator and Director
of Research, and was also Professor of
Molecular Genetics at the University of
Toronto. Tony remained in Toronto for
the rest of his career.
Tony was very much at the center of
an exceptional convergence of several
different areas of basic biomedical
research during the last three decades
of the 20th century, which revolutionized
our understanding of the molecular basis
of cell signaling and malignant transfor-
mation. These important discoveriessevier Inc.contributed to new approaches for the
development of many new cancer drugs.
The molecular basis of cancer was re-
vealed through a stunning explosion of
discoveries. These advances include:
the genetic origins of malignancies; the
mode of action of retroviral oncogenes;
the discoveries of new growth factors
and cytokines that stimulate cell prolifera-
tion, differentiation, and other vital cellular
processes; the methodology to identify
and track genetic changes in cancer
cells; the identification of evolutionary
conserved critical components of cellular
signaling pathways in nematodes and
Drosophila; and biochemical determina-
tion of how signals that are initiated at
the cell surface and are propagated intra-
cellularly by growth factor receptor acti-
vation stimulate cell proliferation and
other basic processes that are required
for cellular homeostasis. Subsequent
application of this new knowledge led to
the development of what is now defined
as cancer-targeted therapies, which
have changed the way in which many
deadly cancers are now being treated.
Tony is perhaps best known for his
identification of the Src homology 2, or
SH2, domain and the resulting concept
of modular interaction domains as key
elements of the molecular infrastructure
of signaling. While inspecting the primary
structure of v-Fps early in his career,
Tony and his colleagues made an impor-
tant observation. They realized that, in
addition to the catalytic tyrosine kinase
domain of v-Fps that is also seen in the
oncogenic Src and Abl tyrosine kinases,
these oncogenic proteins contain a
conserved noncatalytic region of 100
amino acids, which they termed the SH2
domain (the tyrosine kinase is the SH1
domain). Through biochemical analyses
of the tyrosine kinase activities of a variety
of v-Fps mutants and comparison of their
cellular transformation properties, Tony’s
laboratory demonstrated that the v-Fps
SH2 domain plays an important role in
controlling both the tyrosine kinase activ-
ity and cell transformation. Members of
the Src and Abl tyrosine kinase families
contain an additional conserved non-
catalytic region of 60 amino acids,
designated the Src homology 3 (SH3)
domain, located N terminal to the SH2
domain of Src and Abl. Tony proposed
that SH2 and SH3 domains function as
independent protein modules that main-
tain their unique functions in different
host proteins and that they play important
regulatory roles in controlling the activity
and localization of Src and other cyto-
plasmic tyrosine kinases. This concept
of modularity gained significant traction
when the laboratory of Hidesaburo Hana-
fusa found that the transforming gene of
the CT10 retrovirus, v-Crk, encodes a viral
gag protein fused to only SH2 and SH3
domains, demonstrating that SH2 and
SH3 domains can function alone as onco-
genes. The SH2 domain of Crkwas shown
to bind directly to phosphotyrosine
(P-Tyr)-containing proteins, indicating
that SH2 domains may recognize specific
tyrosine-containing regions in a phos-
phorylation-dependent manner. Because
many signaling molecules with different
enzymatic activities, such as phospholi-
pase Cg (PLCg), Ras GTPase-activating
protein (GAP), and the Src family kinases,
contain SH2 domains, this realization pro-
vided a link between activation of cyto-
plasmic and receptor tyrosine kinases
(RTKs). Indeed, experiments performed
in Tony’s and other laboratories demon-
strated that, following their stimulation
with ligands, the EGF receptor (EGFR),
PDGF receptor (PDGFR), and other acti-
vated RTKs form physical complexes
with signaling molecules such as PLCg,
GAP, or adaptor proteins such as Grb2
or Nck by binding to the SH2 domains of
these signaling proteins. For example, in
1992, Tony’s laboratory demonstrated
that complex formation between the scaf-fold protein Shc and phosphotyrosines on
activated EGFR leads to tyrosine phos-
phorylation of Shc, which in turn forms a
complex with the SH2 domain of the
adaptor protein Grb2. Grb2 uses its two
SH3 domains to bind the guanine nucleo-
tide exchange factor Sos so that Shc
effectively recruits Sos to the cell mem-
brane (and thus activates Ras) through
SH2 and SH3 domain-mediated inter-
actions. The resulting activated (GTP-
bound) Ras molecules stimulate a
cascade of three protein kinases, result-
ing in activation and nuclear translocation
of MAP kinase. This highly conserved
signaling pathway relays information
from the cell membrane to the nucleus
and other intracellular compartments to
regulate a variety of EGF-induced cellular
processes.
More than 20 years later, in one of his
last and most elegant articles that was
published in July 2013—only three weeks
before he passed away—Tony’s labora-
tory described a comprehensive analysis
of the cellular functions of Shc at different
time points following EGF stimulation. His
laboratory used mass spectrometry and
other state-of-the-art technologies to
demonstrate that Shc responds to EGF
stimulation in ‘‘multiple waves of distinct
phosphorylation events and protein inter-
actions.’’ In other words, at different time
points following EGF stimulation, Shc
forms distinct complexes with different
positive or negative regulators to control
many of the pleiotropic cellular responses
induced by EGF stimulation. These twoCell 154, Seppublications, spanning more than two
decades of scientific effort, provide
a clear testament to the originality, bril-
liance, and focus that have been a hall-
mark of Tony’s entire scientific career.
In addition to his main interest in eluci-
dating the biological roles and mecha-
nisms underlying the actions of SH2,
SH3, and other small protein modules in
mediating protein-protein and other inter-
actions during signal transduction, Tony’s
laboratory made important contributions
to other fields of biomedical research,
including analysis of molecular mecha-
nisms that govern cellular polarity and
molecular mechanisms that control axon
guidance, as well as systems biology
with an emphasis on elucidation of the
dynamic nature ofmolecular eventsduring
cellular signaling. In all of these studies, he
showed an uncanny ability to marry adva-
nces in technology with the most impor-
tant biological questions to view the entire
cell in terms of itsmolecular infrastructure.
The death of Tony Pawson shocked
and saddened his many colleagues,
former students, postdoctoral fellows,
and friends all over the world. We will
miss Tony’s thoughtful and eloquent lec-
tures. We will miss Tony’s inspiring publi-
cations and the elegance and clarity of his
scientific mind. We will miss our informal
discussions at scientific meetings that
were filled with good humor, Tony’s char-
acteristic chuckle, and his sharp insights.
Tony’s legacy will be remembered and
will be an inspiration for future genera-
tions of scientists.Joseph Schlessinger1,*
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